Skip to main content
Erschienen in: Obesity Surgery 2/2017

27.07.2016 | Original Contributions

Efficacy of First-Time Intragastric Balloon in Weight Loss: a Systematic Review and Meta-analysis of Randomized Controlled Trials

verfasst von: Alan A. Saber, Saeed Shoar, Mahmoud W. Almadani, Natan Zundel, Mohammed J. Alkuwari, Moataz M. Bashah, Raul J. Rosenthal

Erschienen in: Obesity Surgery | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The intragastric balloon (IGB) is an adjunctive treatment for obesity. This meta-analysis aimed to evaluate the efficacy and safety of IGB treatment by reviewing randomized controlled trials (RCTs).

Methods

A total of 20 RCTs involving 1195 patients were identified. Weight loss results before and after 3 months were analyzed separately. The weight loss results of patients with and without IGB treatment were compared.

Results

Our meta-analysis calculated the following significant effect sizes: 1.59 and 1.34 kg/m2 for overall and 3-month BMI loss, respectively; 14.25 and 11.16 % for overall and >3-month percentage of excess weight loss, respectively; 4.6 and 4.77 kg for overall and 3-month weight loss, respectively; and 2.81, 1.62, and 4.09 % for overall, 3-month, and >3-month percent of weight loss, respectively. A significant effect size was calculated that favored fluid-filled IGBs over air-filled IGBs. Flatulence (8.75 vs. 3.89 %, p = 0.0006), abdominal fullness (6.32 vs. 0.55 %, p = 0.001), abdominal pain (13.86 vs. 7.2 %, p = 0.0001), abdominal discomfort (4.37 vs. 0.55 %, p = 0.006), and gastric ulcer (12.5 vs. 1.2 %, p < 0.0001) were significantly more prevalent among IGB patients than among non-IGB control patients. No mortality was reported from IGB treatment.

Conclusion

IGB treatment, in addition to lifestyle modification, is an effective short-term modality for weight loss. However, there is not sufficient evidence confirming its safety or long-term efficacy.
Literatur
1.
Zurück zum Zitat WHO. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2009. WHO. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2009.
2.
Zurück zum Zitat Loveman E, Frampton GK, Shepherd J, et al. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol Assess. 2011;15(2):1–182.CrossRef Loveman E, Frampton GK, Shepherd J, et al. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol Assess. 2011;15(2):1–182.CrossRef
3.
Zurück zum Zitat Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg. 2014;24(3):437–55.CrossRefPubMed Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg. 2014;24(3):437–55.CrossRefPubMed
4.
Zurück zum Zitat Genco A, Lorenzo M, Baglio G, et al. Does the intragastric balloon have a predictive role in subsequent LAP-BAND((R)) surgery? Italian multicenter study results at 5-year follow-up. Surg Obes Relat Dis. 2014;10(3):474–8.CrossRefPubMed Genco A, Lorenzo M, Baglio G, et al. Does the intragastric balloon have a predictive role in subsequent LAP-BAND((R)) surgery? Italian multicenter study results at 5-year follow-up. Surg Obes Relat Dis. 2014;10(3):474–8.CrossRefPubMed
5.
Zurück zum Zitat Paulus GF, de Vaan LE, Verdam FJ, Bouvy ND, Ambergen TA, van Heurn LW. Bariatric surgery in morbidly obese adolescents: a systematic review and meta-analysis. Obes Surg. 2015;25(5):860–78.CrossRefPubMedPubMedCentral Paulus GF, de Vaan LE, Verdam FJ, Bouvy ND, Ambergen TA, van Heurn LW. Bariatric surgery in morbidly obese adolescents: a systematic review and meta-analysis. Obes Surg. 2015;25(5):860–78.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Mathus-Vliegen EM, Tytgat GN, Veldhuyzen-Offermans EA. Intragastric balloon in the treatment of super-morbid obesity. Double-blind, sham-controlled, crossover evaluation of 500-milliliter balloon. Gastroenterology. 1990;99(2):362–9.CrossRefPubMed Mathus-Vliegen EM, Tytgat GN, Veldhuyzen-Offermans EA. Intragastric balloon in the treatment of super-morbid obesity. Double-blind, sham-controlled, crossover evaluation of 500-milliliter balloon. Gastroenterology. 1990;99(2):362–9.CrossRefPubMed
7.
Zurück zum Zitat Hogan RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc. 1989;35(5):381–5.CrossRefPubMed Hogan RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc. 1989;35(5):381–5.CrossRefPubMed
8.
Zurück zum Zitat Ramhamadany EM, Fowler J, Baird IM. Effect of the gastric balloon versus sham procedure on weight loss in obese subjects. Gut. 1989;30(8):1054–7.CrossRefPubMedPubMedCentral Ramhamadany EM, Fowler J, Baird IM. Effect of the gastric balloon versus sham procedure on weight loss in obese subjects. Gut. 1989;30(8):1054–7.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Geliebter A, Westreich S, Gage D. Gastric distention by balloon and test-meal intake in obese and lean subjects. Am J Clin Nutr. 1988;48(3):592–4.PubMed Geliebter A, Westreich S, Gage D. Gastric distention by balloon and test-meal intake in obese and lean subjects. Am J Clin Nutr. 1988;48(3):592–4.PubMed
10.
Zurück zum Zitat Benjamin SB, Maher KA, EL Jr C, et al. Double-blind controlled trial of the Garren-Edwards gastric bubble: an adjunctive treatment for exogenous obesity. Gastroenterology. 1988;95(3):581–8.CrossRefPubMed Benjamin SB, Maher KA, EL Jr C, et al. Double-blind controlled trial of the Garren-Edwards gastric bubble: an adjunctive treatment for exogenous obesity. Gastroenterology. 1988;95(3):581–8.CrossRefPubMed
11.
Zurück zum Zitat Meshkinpour H, Hsu D, Farivar S. Effect of gastric bubble as a weight reduction device: a controlled, crossover study. Gastroenterology. 1988;95(3):589–92.CrossRefPubMed Meshkinpour H, Hsu D, Farivar S. Effect of gastric bubble as a weight reduction device: a controlled, crossover study. Gastroenterology. 1988;95(3):589–92.CrossRefPubMed
12.
Zurück zum Zitat Lindor KD, RW Jr H, Ilstrup DM, Jensen MD. Intragastric balloons in comparison with standard therapy for obesity—a randomized, double-blind trial. Mayo Clin Proc. 1987;62(11):992–6.CrossRefPubMed Lindor KD, RW Jr H, Ilstrup DM, Jensen MD. Intragastric balloons in comparison with standard therapy for obesity—a randomized, double-blind trial. Mayo Clin Proc. 1987;62(11):992–6.CrossRefPubMed
13.
Zurück zum Zitat Garren M, Garren L, Giordano F. The Garren gastric bubble: an Rx for the morbidly obese. Endocr Rev. 1984;1:57–60. Garren M, Garren L, Giordano F. The Garren gastric bubble: an Rx for the morbidly obese. Endocr Rev. 1984;1:57–60.
14.
Zurück zum Zitat Nieben OG, Harboe H. Intragastric balloon as an artificial bezoar for treatment of obesity. Lancet. 1982;1(8265):198–9.CrossRefPubMed Nieben OG, Harboe H. Intragastric balloon as an artificial bezoar for treatment of obesity. Lancet. 1982;1(8265):198–9.CrossRefPubMed
15.
Zurück zum Zitat Giardiello C, Borrelli A, Silvestri E, Antognozzi V, Iodice G, Lorenzo M. Air-filled vs water-filled intragastric balloon: a prospective randomized study. Obes Surg. 2012;22(12):1916–9.CrossRefPubMed Giardiello C, Borrelli A, Silvestri E, Antognozzi V, Iodice G, Lorenzo M. Air-filled vs water-filled intragastric balloon: a prospective randomized study. Obes Surg. 2012;22(12):1916–9.CrossRefPubMed
16.
Zurück zum Zitat De Castro ML, Morales MJ, Del Campo V, et al. Efficacy, safety, and tolerance of two types of intragastric balloons placed in obese subjects: a double-blind comparative study. Obes Surg. 2010;20(12):1642–6.CrossRefPubMed De Castro ML, Morales MJ, Del Campo V, et al. Efficacy, safety, and tolerance of two types of intragastric balloons placed in obese subjects: a double-blind comparative study. Obes Surg. 2010;20(12):1642–6.CrossRefPubMed
17.
Zurück zum Zitat Mathus-Vliegen EM, Eichenberger RI. Fasting and meal-suppressed ghrelin levels before and after intragastric balloons and balloon-induced weight loss. Obes Surg. 2014;24(1):85–94.CrossRefPubMed Mathus-Vliegen EM, Eichenberger RI. Fasting and meal-suppressed ghrelin levels before and after intragastric balloons and balloon-induced weight loss. Obes Surg. 2014;24(1):85–94.CrossRefPubMed
18.
Zurück zum Zitat Mohammed M, Anwar R, Mansour AH, Elmasry E, Othman G. Effects of intragastric balloon versus conservative therapy on appetite regulatory hormones in obese subjects. Trends Med Res. 2014;9(2):58–80.CrossRef Mohammed M, Anwar R, Mansour AH, Elmasry E, Othman G. Effects of intragastric balloon versus conservative therapy on appetite regulatory hormones in obese subjects. Trends Med Res. 2014;9(2):58–80.CrossRef
19.
Zurück zum Zitat Mathus-Vliegen EM, de Groot GH. Fasting and meal-induced CCK and PP secretion following intragastric balloon treatment for obesity. Obes Surg. 2013;23(5):622–33.CrossRefPubMed Mathus-Vliegen EM, de Groot GH. Fasting and meal-induced CCK and PP secretion following intragastric balloon treatment for obesity. Obes Surg. 2013;23(5):622–33.CrossRefPubMed
20.
Zurück zum Zitat Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity (Silver Spring). 2013;21(8):1561–70.CrossRef Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity (Silver Spring). 2013;21(8):1561–70.CrossRef
21.
Zurück zum Zitat Ponce J, Quebbemann BB, Patterson EJ. Prospective, randomized, multicenter study evaluating safety and efficacy of intragastric dual-balloon in obesity. Surg Obes Relat Dis. 2013;9(2):290–5.CrossRefPubMed Ponce J, Quebbemann BB, Patterson EJ. Prospective, randomized, multicenter study evaluating safety and efficacy of intragastric dual-balloon in obesity. Surg Obes Relat Dis. 2013;9(2):290–5.CrossRefPubMed
22.
Zurück zum Zitat Genco A, Maselli R, Frangella F, et al. Effect of consecutive intragastric balloon (BIB(R)) plus diet versus single BIB(R) plus diet on eating disorders not otherwise specified (EDNOS) in obese patients. Obes Surg. 2013;23(12):2075–9.CrossRefPubMed Genco A, Maselli R, Frangella F, et al. Effect of consecutive intragastric balloon (BIB(R)) plus diet versus single BIB(R) plus diet on eating disorders not otherwise specified (EDNOS) in obese patients. Obes Surg. 2013;23(12):2075–9.CrossRefPubMed
23.
Zurück zum Zitat Lee YM, Low HC, Lim LG, et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc. 2012;76(4):756–60.CrossRefPubMed Lee YM, Low HC, Lim LG, et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc. 2012;76(4):756–60.CrossRefPubMed
24.
Zurück zum Zitat Farina MG, Baratta R, Nigro A, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg. 2012;22(4):565–71.CrossRefPubMed Farina MG, Baratta R, Nigro A, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg. 2012;22(4):565–71.CrossRefPubMed
25.
Zurück zum Zitat Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18(12):1611–7.CrossRefPubMed Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18(12):1611–7.CrossRefPubMed
26.
Zurück zum Zitat Fernandes M, Atallah AN, Soares BG, et al. Intragastric balloon for obesity. Cochrane Database Syst Rev. 2007(1):CD004931. Fernandes M, Atallah AN, Soares BG, et al. Intragastric balloon for obesity. Cochrane Database Syst Rev. 2007(1):CD004931.
27.
Zurück zum Zitat Zheng Y, Wang M, He S, Ji G. Short-term effects of intragastric balloon in association with conservative therapy on weight loss: a meta-analysis. J Transl Med. 2015;13:246.CrossRefPubMedPubMedCentral Zheng Y, Wang M, He S, Ji G. Short-term effects of intragastric balloon in association with conservative therapy on weight loss: a meta-analysis. J Transl Med. 2015;13:246.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, Sendra-Gutierrez JM, Gonzalez-Enriquez J. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6.CrossRefPubMed Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, Sendra-Gutierrez JM, Gonzalez-Enriquez J. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6.CrossRefPubMed
29.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94.CrossRefPubMed Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94.CrossRefPubMed
30.
Zurück zum Zitat Mathus-Vliegen EM, Tygat GN. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol. 2002;37(11):1246–52.CrossRefPubMed Mathus-Vliegen EM, Tygat GN. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol. 2002;37(11):1246–52.CrossRefPubMed
31.
Zurück zum Zitat Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61(1):19–27.CrossRefPubMed Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61(1):19–27.CrossRefPubMed
32.
Zurück zum Zitat Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30(1):129–33.CrossRef Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30(1):129–33.CrossRef
33.
Zurück zum Zitat Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11(4):874–81.CrossRefPubMed Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11(4):874–81.CrossRefPubMed
34.
Zurück zum Zitat Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes0020Surg. 2005;15(8):1161–4. Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes0020Surg. 2005;15(8):1161–4.
35.
Zurück zum Zitat Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–38 .e5CrossRefPubMed Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–38 .e5CrossRefPubMed
36.
Zurück zum Zitat Rigaud D, Trostler N, Rozen R, Vallot T, Apfelbaum M. Gastric distension, hunger and energy intake after balloon implantation in severe obesity. Int J Obes Relat Metab Disord. 1995;19(7):489–95.PubMed Rigaud D, Trostler N, Rozen R, Vallot T, Apfelbaum M. Gastric distension, hunger and energy intake after balloon implantation in severe obesity. Int J Obes Relat Metab Disord. 1995;19(7):489–95.PubMed
37.
Zurück zum Zitat Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17(5):649–57.CrossRefPubMed Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17(5):649–57.CrossRefPubMed
38.
Zurück zum Zitat Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20(11):1496–500.CrossRefPubMed Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20(11):1496–500.CrossRefPubMed
Metadaten
Titel
Efficacy of First-Time Intragastric Balloon in Weight Loss: a Systematic Review and Meta-analysis of Randomized Controlled Trials
verfasst von
Alan A. Saber
Saeed Shoar
Mahmoud W. Almadani
Natan Zundel
Mohammed J. Alkuwari
Moataz M. Bashah
Raul J. Rosenthal
Publikationsdatum
27.07.2016
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 2/2017
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-016-2296-8

Weitere Artikel der Ausgabe 2/2017

Obesity Surgery 2/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.